ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,381.35
0.33%
Dow Jones
39,387.76
0.85%
Gold vs US Dollar
2,348.485
0.07%
Brent Oil
84.085
0.16%
Bitcoin
62,900.77
-0.23%
Pepperstone
Advertisement
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. FibroGen Inc (FGEN)

  7. FibroGen Inc (FGEN) News

FibroGen (FGEN)

FibroGen Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:FGEN
DateTimeSourceHeadlineSymbolCompany
07/05/202416:55AllPennyStocks.comTraders Rush To Buy Biotech Following Q1 Earnings BeatNASDAQ:FGENFibroGen Inc
07/05/202412:00GlobeNewswire Inc.FibroGen to Participate in Upcoming Investor ConferencesNASDAQ:FGENFibroGen Inc
06/05/202421:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:FGENFibroGen Inc
06/05/202421:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FGENFibroGen Inc
06/05/202421:02GlobeNewswire Inc.FibroGen Reports First Quarter 2024 Financial ResultsNASDAQ:FGENFibroGen Inc
29/04/202412:00GlobeNewswire Inc.FibroGen to Report First Quarter 2024 Financial ResultsNASDAQ:FGENFibroGen Inc
24/04/202421:02GlobeNewswire Inc.FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology ANASDAQ:FGENFibroGen Inc
02/04/202422:46GlobeNewswire Inc.FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate CancerNASDAQ:FGENFibroGen Inc
26/03/202411:00GlobeNewswire Inc.FibroGen to Present at 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:FGENFibroGen Inc
11/03/202411:00GlobeNewswire Inc.FibroGen Appoints Deyaa Adib, M.D. as Chief Medical OfficerNASDAQ:FGENFibroGen Inc
09/03/202400:19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FGENFibroGen Inc
09/03/202400:18Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FGENFibroGen Inc
09/03/202400:17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FGENFibroGen Inc
26/02/202421:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:FGENFibroGen Inc
26/02/202421:06GlobeNewswire Inc.FibroGen Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:FGENFibroGen Inc
26/02/202421:05GlobeNewswire Inc.FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South KoreaNASDAQ:FGENFibroGen Inc
24/02/202401:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FGENFibroGen Inc
24/02/202401:29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FGENFibroGen Inc
24/02/202401:28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FGENFibroGen Inc
20/02/202412:00GlobeNewswire Inc.FibroGen to Report Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:FGENFibroGen Inc
14/02/202420:37Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:FGENFibroGen Inc
06/02/202401:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FGENFibroGen Inc
05/02/202412:00GlobeNewswire Inc.FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024NASDAQ:FGENFibroGen Inc
25/01/202412:00GlobeNewswire Inc.FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network’s Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic CancerNASDAQ:FGENFibroGen Inc
27/12/202300:28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FGENFibroGen Inc
11/12/202321:21Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FGENFibroGen Inc
11/12/202321:20Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FGENFibroGen Inc
11/12/202321:19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:FGENFibroGen Inc
09/12/202322:02GlobeNewswire Inc.FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual MeetingNASDAQ:FGENFibroGen Inc
06/11/202321:11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:FGENFibroGen Inc
 Showing the most relevant articles for your search:NASDAQ:FGEN

Your Recent History

LSE
ITM
Itm Power
LSE
TYM
Tertiary Minerals
LSE
AGL
Angle
LSE
PEN
Pennant
NYSE
SPCE
Virgin Galactic
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved